The uniqueness of the spa resort, on the beachfront land of 4.5 acres, lies in its architecture and interior design by Lek Bunnag that reflects Khmer cultural heritage with the tint of Arabian harem. The spa and treatment area - a small labyrinth enclosed in ochre red, dark blue walls and corridors with exotic decoration and water elements throughout suggest a journey in another world, different from usual day-to-day scenes.
The therapists here combine Ancient Thai healing practices with world class service and knowledge to create a treatment personalized to each visitor. The treatments concern Thai belief of maintaining vitality and balance of the 4 elements – water, earth, air, and fire.
Many women are familiar with the brand name BOTOX® Cosmetic (onabotulinumtoxinA), but a new study from SheSpeaks™, an online community of women, reveals what they really want to know about it.1 To address the most common questions women have – and there are nearly 10 million women who are considering treatment2 – Allergan Inc., maker of BOTOX® Cosmetic, teamed up with SheSpeaks to identify these questions and provide answers.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7334951-allergan-shespeaks-survey-reveals-what-u-s-women-really-want-to-know-about-botox-cosmetic/
Oro Valley Audiology
2542 E Vistoso Commerce Loop Rd, Tucson, AZ 85755, USA
(520) 825-4770
http://hearintucson.com
https://www.google.com/maps?cid=7471816986561274177
https://www.google.com/search?q=Oro+Valley+Audiology&kponly&kgmid=/g/1thx4hd3
As the name suggests, and audiologist is a health-care professional who concentrates on the medical diagnoses, recognition, tracking and treatment of conditions of the auditory and vestibular parts of the ear. These specialists dispense hearing aids, manage and fix up hearing problems and evaluate candidacy for cochlear implants. An audiologist helps style and carry out individual and industrial hearing safety programs, newborn hearing screening programs, and school hearing screening programs.
Audiologists have training in anatomy and physiology, hearing aids, cochlear implants, electrophysiology, acoustics, psychophysics, neurology, vestibular function and evaluation, balance disorders, therapy and indication language. Unfortunately, hearing loss is prevalent throughout the U.S.
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
In this anemia kindle e-book or paperback,
Quick and Easy Diet Cures 4 Iron Deficiency Anemia,
I provide you with powerful information that you need to get a cure for anemia. Doctors don’t give you this treatment for anemia because they don’t have this information or they are not allowed to use natural ways to help with your condition
Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel.
Mirvaso® is an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours.1 It is indicated for the symptomatic treatment of facial erythema (redness) of rosacea in adult patients.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65011-mirvaso-first-and-only-treatment-rosacea
Many people have an inflamed body and don’t know it. They are surprised when they develop arthritis, muscle pain, acid reflux, hiatus hernia, or gout. So how did they get to this point? All disease takes time to develop and gout is no different.
On World Mental Health Day, Janssen has announced the results of a pan-European research project: ‘Talking About Treatment in Schizophrenia: A Patient and Carer Survey’. The survey of 166 adults living with schizophrenia and 468 carers was conducted by the independent market research agency, Fieldwork International (part of Ipsos MORI), and explored awareness, feelings and preferences regarding treatment.
The survey, conducted across 12 countries in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Russia, Spain, Sweden, Switzerland and the UK), highlighted key factors affecting the peace of mind for carers, such as the impact of the condition on day‑to-day life, potential relapse/hospitalisation and getting support beyond medication. 94% stated they reminded the person they care for to take their medication and for 49% this happens often.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7947151-janssen-survey-carers-adults-schizophrenia/
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
Syneron Medical Ltd., the leading global aesthetic device company, announced to a group of international media its new activities and enhanced global commitment to developing the non-invasive body shaping market, one of the fastest growing segments in the global aesthetic medical device market. The press conference took place at the Academy of Medical Sciences in London, just prior to the opening of the BODY Conference and Exhibition, which took place in London on November 3-4, 2012 and for which Syneron was the main sponsor.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58631-body-shaping-by-syneron
DePuy Synthes Companies today announced the launch of Hit Play, an educational initiative that encourages those dealing with hip or knee pain to stop settling for a life on ‘pause’ and instead take action to get back to the activities and people they love most.
Osteoarthritis is one of the most common reasons for severe hip or knee pain, affecting nearly 27 million Americans today and will potentially affect up to 67 million people by 2030.1,2 In turn, demand for hip and knee replacements are expected to dramatically increase, yet many women see joint replacement as a “last resort” and often wait until the pain has become unbearable before turning to surgery. Through a series of compelling and relatable content, DePuy Synthes seeks to inspire the millions of people stuck on ‘pause’ due to hip or knee pain to explore joint replacement with a doctor, as a potential viable solution when they Hit Play.
To view the multimedia release go to:
http://www.multivu.com/players/English/79644241-lysol-madison-square-bgca-expose-germs/
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
